September 11, 2017 — Veniti Inc. announced that Boston Scientific will distribute the Vici Venous Stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed.
Launched in 2014, the Vici Venous Stent has gained wide market acceptance for its balance of end-to-end strength, flexibility and lumen quality to address the challenging requirements of venous disorders. It is available in a conventional delivery system, as well as the novel Vici Verto Venous Stent System, providing more control in the landing of stents in areas of critical blood flow.
Veniti is currently conducting the VIRTUS Trial to evaluate the safety and efficacy of the Vici Venous Stent for the treatment of chronic iliofemoral venous outflow obstruction under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption.
For more information: www.veniti.com